Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

32.180
-1.740-5.13%
Volume:12.23M
Turnover:402.68M
Market Cap:195.14B
PE:29.56
High:34.560
Open:34.040
Low:32.120
Close:33.920
52wk High:43.587
52wk Low:27.658
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:1.50
T/O Rate:0.20%
Dividend:0.49
Dividend Rate:1.51%
EPS(LYR):1.089
ROE:19.40%
ROA:9.08%
PB:4.41
PE(LYR):29.56
PS:10.49

Loading ...

Movement Alert|HANSOH PHARMA Rises 3.6% in Regular Trading, New Drug HS-10582 Receives NMPA Clinical Trial Approval

Market Focus
·
Aug 07

Hansoh Pharma Receives NMPA Clearance for HS-10582 Phase I Clinical Trials in Hypercholesterolemia

Bulletin Express
·
Aug 06

HANSOH PHARMA Receives Clinical Trial Approval for HS-10582 Tablets

Stock News
·
Aug 06

Hansoh Pharmaceutical - Clinical Trial Approval for Hs-10582 Tablets Issued By- National Medical Products Administration

THOMSON REUTERS
·
Aug 06

Hansoh Pharma Sets 26 Aug 2026 Board Meeting to Review 1H26 Results and Interim Dividend

Bulletin Express
·
Aug 04

HANSOH PHARMA July 2026 Share Capital Update: No Change in Issued Shares; HKD 4.68 Billion Convertibles Outstanding

Bulletin Express
·
Aug 04

Hansoh Pharmaceutical Group Stock Slides 2.1% in Hong Kong

Dow Jones
·
Aug 03

Movement Alert|HANSOH PHARMA Declines 3.05% in Regular Trading, Trading at 31.16 HKD

Market Focus
·
Aug 03

Movement Alert|HANSOH PHARMA Falls 3.04% in Regular Trading, Pharmaceutical Sector Broadly Under Pressure

Market Focus
·
Jul 30

Hansoh Pharmaceutical Group Stock Rallies 3.7% in Hong Kong

Dow Jones
·
Jul 29

Offshore Wind Tendering Heats Up in July as ASMPT Posts Strong Interim Profit Jump

Stock News
·
Jul 29

GSK Q2 Sales Beat Analyst Estimates on Specialty Medicines Growth

Reuters
·
Jul 28

GSK, Hansoh's Cancer Drug Meets Main Goal of Bone Cancer Trial

Reuters
·
Jul 28

Hansoh Pharma's HS-20093 Achieves Primary Goal in Phase III Osteosarcoma Study

Stock News
·
Jul 28

Hansoh Pharma Says Artemis-011 Phase 3 Trial of Hs-20093 Meets Primary PFS Endpoint in Osteosarcoma

Reuters
·
Jul 28

Hansoh Pharmaceutical - to Initiate Biologics License Application Process in China in the Near Term

THOMSON REUTERS
·
Jul 28

Hansoh Pharmaceutical - Phase Iii Clinical Study of Hs-20093 in Treatment- of Osteosarcoma Has Met Primary Endpoint

THOMSON REUTERS
·
Jul 28

CLSA Maintains Positive Rating on Hansoh Pharma, Raises Price Target to HK$42

Deep News
·
Jul 28

Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$37.24 From HK$38, Keeps at Neutral

MT Newswires Live
·
Jul 27

Oral Cyclic Peptides Enter Validation Phase, Opening a Multi-Billion Dollar Therapeutic Arena

Stock News
·
Jul 22